Skip to content

Effect of COVID-19 Pandemic on Behavioral and Pharmacological Treatment Outcomes in ADHD Children

Effect of COVID-19 Pandemic on Behavioral and Pharmacological Treatment Outcomes in Attention Deficit Hyperactivity Disorder (ADHD) Children

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
TCTR
Registry ID
TCTR20220714003
Enrollment
80
Registered
2022-07-14
Start date
2023-09-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ADHD children COVID-19 Pandemic, Behavioral and Pharmacological Treatment Outcomes , Attention Deficit Hyperactivity Disorder (ADHD) Children

Interventions

They were Thai children with ADHD who received the providing from Rajanagarindra Institute of Child Development, Chiang Mai, Thailand. And, They had the worson behavioral outcomes and pharmacological
Supportive Care,Supportive Care

Sponsors

Faculty of Pharmaceutical Sciences, Burapha University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 14 Years

Inclusion criteria

Inclusion criteria: 1) was Thai people with 13-digit identification. 2) aged 14 years or younger during COVID-19 outbreak (after 3 April 2020). 3) were diagnosed Attention Deficit Hyperactivity Disorder (ADHD): ICD-10-TM codes F90 before and during COVID-19 outbreak. 4) had at least one patient data recorded or medical record before and during COVID-19 outbreak. 5) had records of pharmacological outcome or behavioral outcome. 6) had records of demographic data, Covid-19 pandemic data, or clinical and pharmacological factors.

Exclusion criteria

Exclusion criteria: 1) denied to participate in this project. 2) were diagnosed Autistic traits who would be represented the unobvious differentiation of pharmacological outcome and behavioral outcome. 3) loss of follow up or loss of contact information. 4) were study subjects with missing data on pharmacological outcome, behavioral outcome, demographic data, Covid-19 pandemic data, or clinical and pharmacological factors.

Design outcomes

Primary

MeasureTime frame
behavioral outcomes survey date parents SNAP IV rating scale or health care provider assessment

Secondary

MeasureTime frame
Pharmacological outcomes survey date medication possession ratio (MPR) or medication adherence assessment by physician or medication withdraw period more than 6 months in the comparison of before and after COVID-19 pandemic

Countries

Thailand

Contacts

Public ContactPongpan Suriyong

Faculty of Pharmaceutical Sciences, Burapha University

pongpans@go.buu.ac.th0616565943

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026